Wang et al. [61] found that PRDX3 expression was significantly higher in the platinum-resistant serous ovarian cancer, in stages III and IV, and in moderately and poorly differentiated ovarian cancer tissues compared with their platinum-sensitive counterparts, they therefore concluded that PRDX3 was associated with drug resistance in ovarian cancer. Here, PRDX3 is linked to ovarian serous adenocarcinoma.